Conditions: Choroidal Neovascularization (CNV)
Keywords: Vision Impairment Abnormal growth of blood vessels
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 183
Healthy volunteers: no

Brief summary:
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).

Detailed description:

Arms:
arm 1: A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity. arm 2: Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.

Interventions: intervention 1: Ranibizumab intervention 2: Sham control
Intervention descriptions: intervention 1: Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant. intervention 2: The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.

Protocol document: